

# Senseonics to Participate in the Raymond James Life Sciences and MedTech Conference



June 04, 2019

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Raymond James Life Sciences and MedTech Conference in New York, NY.

Management is scheduled to present Tuesday, June 18, 2019 at 4:10pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at [www.senseonics.com](http://www.senseonics.com).

## About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense<sup>®</sup> and Eversense<sup>®</sup> XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20190604005767/en/>

## Senseonics Investor Relations Contact:

Lynn Lewis or Philip Taylor

Investor Relations

415-937-5406

[Investors@senseonics.com](mailto:Investors@senseonics.com)

Source: Senseonics Holdings, Inc.